For Patients and Physicians
Content
For patients and physicians, we provide medicines for some of the world’s most serious diseases. For the people who pay for healthcare, we work to make sure that our medicines offer real value for money. For our employees, we provide a culture in which they can feel appreciated, energised and rewarded for their contribution. For our shareholders, we aim to deliver value through our continued focus on innovation and running our business efficiently. For the wider community, we want to be valued for the contribution our medicines can make to society and trusted for the way in which we do business.
We work closely with all our stakeholders to understand their challenges and how we can combine our skills and resources to achieve a common goal: improved health.
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company.
Our mission is to make a meaningful difference to patient health through great medicines that bring benefit for patients and add value for our stakeholders and society.
We discover, develop, manufacture and market prescription medicines for six important areas of healthcare, which include some of the world’s most serious illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.
Read more about our medicines
We also work with others to combine complementary skills and strengthen the platform for success in meeting a common goal: improved healthcare.
Find out more about partnering with us
We are active in over 100 countries with a growing presence in emerging markets including China, Brazil, Mexico and Russia.
We employ over 57,200 people (46% in Europe, 31% in the Americas and 23% in Asia-Pacific).
Read more about our employees and our culture
We invest over $4 billion in R&D each year. About 11,300 work in our R&D organisation, we have 14 principal R&D centres in eight countries, and 9,600 employees work at our Supply & Manufacturing sites in 16 countries
AstraZeneca was formed on 6 April 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK – two companies with similar sciencebased cultures and a shared vision of the pharmaceutical industry.
The merger aimed to improve the combined companies’ ability to deliver long term growth and enduring shareholder value through: Global power & reach in sales and marketing
Ability to deliver the potential of existing and future products through the power and reach of a combined global sales and marketing resource Widespread class coverage in key therapy areas, such as cardiovascular and respiratory disease, due to complementary nature of products Major primary care presence, particularly in gastrointestinal, cardiovascular and respiratory medicine
Leading position in a number of specialist/hospital markets, including oncology and anaesthesia
Stronger R&D platform for innovation-led growth
Substantial research and development (R&D) expenditure Strong combined development pipeline Potential for further strengthening of the pipeline by enhanced discovery and development capability through greater scale and focus on selected areas and technologies
Greater financial strategic flexibility
Financial strength and scale to give AstraZeneca's management greater strategic flexibility to drive long-term earnings growth
Substantial operational efficiencies resulting in cost savings
We work closely with all our stakeholders to understand their challenges and how we can combine our skills and resources to achieve a common goal: improved health.
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company.
Our mission is to make a meaningful difference to patient health through great medicines that bring benefit for patients and add value for our stakeholders and society.
We discover, develop, manufacture and market prescription medicines for six important areas of healthcare, which include some of the world’s most serious illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.
Read more about our medicines
We also work with others to combine complementary skills and strengthen the platform for success in meeting a common goal: improved healthcare.
Find out more about partnering with us
We are active in over 100 countries with a growing presence in emerging markets including China, Brazil, Mexico and Russia.
We employ over 57,200 people (46% in Europe, 31% in the Americas and 23% in Asia-Pacific).
Read more about our employees and our culture
We invest over $4 billion in R&D each year. About 11,300 work in our R&D organisation, we have 14 principal R&D centres in eight countries, and 9,600 employees work at our Supply & Manufacturing sites in 16 countries
AstraZeneca was formed on 6 April 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK – two companies with similar sciencebased cultures and a shared vision of the pharmaceutical industry.
The merger aimed to improve the combined companies’ ability to deliver long term growth and enduring shareholder value through: Global power & reach in sales and marketing
Ability to deliver the potential of existing and future products through the power and reach of a combined global sales and marketing resource Widespread class coverage in key therapy areas, such as cardiovascular and respiratory disease, due to complementary nature of products Major primary care presence, particularly in gastrointestinal, cardiovascular and respiratory medicine
Leading position in a number of specialist/hospital markets, including oncology and anaesthesia
Stronger R&D platform for innovation-led growth
Substantial research and development (R&D) expenditure Strong combined development pipeline Potential for further strengthening of the pipeline by enhanced discovery and development capability through greater scale and focus on selected areas and technologies
Greater financial strategic flexibility
Financial strength and scale to give AstraZeneca's management greater strategic flexibility to drive long-term earnings growth
Substantial operational efficiencies resulting in cost savings
